FDA reviewers argued RECIST v1.1 response and DoR may be inflated because injected-lesion shrinkage could represent local ...
Formulary decisions commonly restrict access to T2D and weight loss, creating coverage blind spots as GLP-1 trials mature across broader cardiometabolic and organ-protection indications. Utilization ...
Earlier this year, a report from Pharmaceutical Executive detailed the ways in which China is becoming an essential R&D partner for pharma and biotech companies. According to the ...
This episode of The Ron Lanton Report examines why the next phase of healthcare innovation will be constrained not by capital or technology, but by people. Framing the discussion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results